Minireviews
Copyright ©The Author(s) 2020.
World J Gastroenterol. Apr 28, 2020; 26(16): 1888-1900
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1888
Figure 1
Figure 1 First and second line therapies for advanced hepatocellular carcinoma. RECIST: Response Evaluation Criteria for Solid Tumors; ECOG: Eastern Cooperative Oncology Group; SOR: Sorafenib.